Karyopharm Therapeutics Inc (NASDAQ:KPTI) insider Sharon Shacham sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $10.08, for a total value of $100,800.00. Following the completion of the sale, the insider now owns 723,510 shares in the company, valued at approximately $7,292,980.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Sharon Shacham also recently made the following trade(s):
- On Thursday, December 7th, Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $10.39, for a total value of $103,900.00.
Shares of Karyopharm Therapeutics Inc (KPTI) traded down $0.74 during trading on Tuesday, reaching $10.04. The company had a trading volume of 333,407 shares, compared to its average volume of 200,470. Karyopharm Therapeutics Inc has a one year low of $7.48 and a one year high of $14.63. The company has a market cap of $508.61, a PE ratio of -3.79 and a beta of 4.09.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, November 2nd. The company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. research analysts anticipate that Karyopharm Therapeutics Inc will post -2.58 EPS for the current fiscal year.
A number of institutional investors have recently made changes to their positions in KPTI. Voya Investment Management LLC increased its stake in Karyopharm Therapeutics by 42.1% in the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after buying an additional 4,444 shares in the last quarter. Tudor Investment Corp ET AL purchased a new stake in Karyopharm Therapeutics in the 2nd quarter worth $136,000. State of Wisconsin Investment Board purchased a new stake in Karyopharm Therapeutics in the 2nd quarter worth $235,000. The Manufacturers Life Insurance Company increased its stake in Karyopharm Therapeutics by 26.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock worth $243,000 after buying an additional 5,586 shares in the last quarter. Finally, ProShare Advisors LLC increased its stake in Karyopharm Therapeutics by 8.0% in the 2nd quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock worth $246,000 after buying an additional 2,021 shares in the last quarter. 60.92% of the stock is currently owned by institutional investors.
Several analysts have commented on KPTI shares. Cantor Fitzgerald reiterated a “buy” rating and set a $18.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, September 20th. Jefferies Group reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. Royal Bank of Canada reiterated a “buy” rating and set a $14.00 target price on shares of Karyopharm Therapeutics in a research note on Wednesday, October 18th. Robert W. Baird reissued a “buy” rating on shares of Karyopharm Therapeutics in a report on Friday, November 3rd. Finally, Zacks Investment Research cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, November 7th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $17.33.
COPYRIGHT VIOLATION NOTICE: “Karyopharm Therapeutics Inc (NASDAQ:KPTI) Insider Sells $100,800.00 in Stock” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/16/karyopharm-therapeutics-inc-kpti-insider-sells-100800-00-in-stock.html.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.